AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report)'s stock price fell 3.4% during trading on Monday . The stock traded as low as $2.46 and last traded at $2.44. 261,978 shares were traded during trading, a decline of 89% from the average session volume of 2,320,570 shares. The stock had previously closed at $2.52.
Wall Street Analysts Forecast Growth
ABCL has been the subject of several research analyst reports. Benchmark reaffirmed a "hold" rating on shares of AbCellera Biologics in a research note on Monday, March 3rd. Stifel Nicolaus lowered their target price on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Finally, KeyCorp cut their price target on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th.
Get Our Latest Stock Analysis on ABCL
AbCellera Biologics Trading Up 2.5 %
The firm has a market capitalization of $727.09 million, a PE ratio of -4.00 and a beta of 0.45. The stock's 50 day moving average price is $2.91 and its two-hundred day moving average price is $2.82.
Hedge Funds Weigh In On AbCellera Biologics
Institutional investors have recently made changes to their positions in the stock. DKM Wealth Management Inc. purchased a new stake in AbCellera Biologics during the 4th quarter worth about $29,000. State of New Jersey Common Pension Fund D acquired a new stake in shares of AbCellera Biologics during the 4th quarter worth about $36,000. Balyasny Asset Management L.P. purchased a new stake in shares of AbCellera Biologics during the fourth quarter worth about $40,000. Mariner LLC acquired a new position in shares of AbCellera Biologics in the fourth quarter valued at approximately $42,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of AbCellera Biologics in the fourth quarter valued at approximately $46,000. 61.42% of the stock is owned by institutional investors and hedge funds.
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Further Reading
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
